AMA announces provisional CPT codes for Pfizer’s pediatric COVID-19 vaccine

The AMA has announced provisional CPT vaccine and administration codes for the Pfizer-BioNTech pediatric COVID-19 vaccine.

The codes “will be effective for use” if Pfizer-BioNTech’s two-dose pediatric vaccine regimen receives FDA approval or emergency use authorization, the AMA said in a press release.

The AMA stated that the vaccine product code is:

• 91307 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use.

The vaccine administration codes are:

• 0071A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose; and
• 0072A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose.

The New York Times reported earlier today that Pfizer and BioNtech asked the FDA to issue an emergency use authorization for their COVID-19 vaccine in children aged 5 to 11 years. Last month, the companies released data from a phase 2/3 study that indicated the vaccine was safe and generated “robust” neutralizing antibody titers. The FDA has previously said it plans to hold a Vaccines and Related Biological Products Advisory Committee meeting on Oct. 26 to “inform the agency’s decision-making” regarding the vaccine.

References:

AMA announces CPT update for pediatric COVID-19 vaccine candidate. https://www.ama-assn.org/press-center/press-releases/ama-announces-cpt-update-pediatric-covid-19-vaccine-candidate. Published Oct. 6, 2021. Accessed Oct. 7, 2021.

FDA to hold advisory committee meetings to discuss emergency use authorization for booster doses and COVID-19 vaccines for younger children. https://www.fda.gov/news-events/press-announcements/fda-hold-advisory-committee-meetings-discuss-emergency-use-authorization-booster-doses-and-covid-19. Published Oct. 1, 2021. Accessed Oct. 7, 2021.

Pfizer asks FDA to authorize its COVID-19 vaccine for children 5 to 11. https://www.nytimes.com/2021/10/07/us/politics/pfizer-fda-authorization-children-5-11. Published Oct. 7, 2021. Accessed Oct. 7, 2021.